Owner Scorecard


← All companies ← NAT Manual NCEW → ← NATR Pharmaceuticals NKTR →

NBTX, Nanobiotix S.A.

Pharmaceuticals consumer brand Unprofitable

We are a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients.

The objective of this physics-based approach is to allow our nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system.

Our most advanced platform has produced lead product candidate JNJ-1900 (NBTXR3) 2 .

Latest annual: FY2025 20-F · figures as filed, in EUR · 1 ADS = 1 ordinary share
NBTX · Nanobiotix S.A.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
€33M
−553.2% YoY · 67% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue €33M 5-yr avg €14M
Operating margin −33.2% 5-yr avg −424.1%
Owner-earnings margin −104% 5-yr avg −354%
Free cash flow margin −104% 5-yr avg −354%

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No meaningful revenue yet; the record is the cash on hand against the burn.
What moves the needle
Operating margin has reached 951% at its best but run negative through the cycle (median −978%) — so the question is which reading is truer: whether the median was pulled below zero by one-off charges, by the cycle, or by spending it is still growing into, and whether it settles back at a profit. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2018–2025

realized figures from each filing · older years to the left
2018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMDec 2025
Income statement
€3M€3M€3M€3M€5M€36M(€7M)€33M€33MRevenueRevenue
(€30M)(€47M)(€36M)(€53M)(€47M)(€27M)(€68M)(€11M)(€11M)Operating incomeOp. inc.
−864.2%n/mn/mn/m−977.8%−74.0%951.1%−33.2%−33.2%Operating marginOp. mgn
(€30M)(€51M)(€34M)(€47M)(€57M)(€40M)(€68M)(€24M)(€24M)Net incomeNet inc.
Cash flow & returns
(€26M)(€41M)(€28M)(€30M)(€37M)(€12M)(€20M)(€33M)(€33M)Operating cash flowOp. cash
€619K€2M€2M€2M€2M€2M€2M€1M€1MDepreciationDeprec.
€4M€8M€4M€16M€18M€26M€47M(€11M)(€11M)Working capital & otherWC & other
€416K€1M€96K€228K€92K€328K€846K€538K€538KCapexCapex
12.0%42.9%3.8%8.6%1.9%0.9%−11.8%1.7%1.7%Capex / revenueCapex/rev
(€26M)(€42M)(€28M)(€30M)(€37M)(€13M)(€20M)(€34M)(€34M)Owner earningsOwner earn.
−758.9%n/mn/mn/m−778.8%−35.4%283.6%−104.2%−104.2%Owner earnings marginOE mgn
(€26M)(€42M)(€28M)(€30M)(€37M)(€13M)(€20M)(€34M)(€34M)Free cash flowFCF
−758.9%n/mn/mn/m−778.8%−35.4%283.6%−104.2%−104.2%Free cash flow marginFCF mgn
-213%-48%-176%Return on equityROE
−213%−48%−176%Retained to equityRetained/eq
Balance sheet
€36M€35M€119M€84M€41M€75M€50M€53M€53MCash & investmentsCash+inv
€11K€62K€0€101K€905K€3M€2M€2MReceivablesReceiv.
€8M€7M€6M€10M€18M€20M€9M€9MAccounts payablePayables
(€8M)(€7M)(€6M)(€10M)(€17M)(€17M)(€7M)(€7M)Operating working capitalOper. WC
€43M€125M€93M€52M€87M€61M€63M€63MCurrent assetsCur. assets
€12M€19M€37M€38M€50M€59M€58M€58MCurrent liabilitiesCur. liab.
3.5×6.6×2.5×1.4×1.8×1.0×1.1×1.1×Current ratioCurr. ratio
€52M€134M€102M€60M€94M€67M€68M€68MTotal assetsAssets
(€36M)(€35M)(€119M)(€84M)(€41M)(€75M)(€50M)(€53M)(€53M)Net debt / (cash)Net debt
-20.8×-9.4×-67.4×-3.4×-1.8×-9.1×-0.7×-0.7×Interest coverageInt. cov.
€14M(€2M)€70M€27M(€27M)(€2M)(€66M)(€84M)(€84M)Shareholders’ equityEquity
Per share
19.63B21.63B24.4M34.7M34.9M36.9M47.3M47.8M47.82BShares out (diluted)Shares
€0.00€0.00€0.10€0.08€0.14€0.98€-0.15€0.68€0.00Revenue / shareRev/sh
€-0.00€-0.00€-1.38€-1.35€-1.64€-1.08€-1.44€-0.50€-0.00EPS (diluted)EPS
€-0.00€-0.00€-1.13€-0.87€-1.07€-0.35€-0.43€-0.71€-0.00Owner earnings / shareOE/sh
€-0.00€-0.00€-1.13€-0.87€-1.07€-0.35€-0.43€-0.71€-0.00Free cash flow / shareFCF/sh
€0.00€0.00€0.00€0.01€0.00€0.01€0.02€0.01€0.00Cap. spending / shareCapex/sh
€0.00€-0.00€2.89€0.77€-0.78€-0.05€-1.39€-1.77€-0.00Book value / shareBVPS

The diluted share count moved ×1/887.05 into 2020 — shares retired, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1.42 into 2021 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

The diluted share count moved ×1000 into TTM — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Per-share growththe realized rate an owner's share compounded
7-yr5-yr
Revenue / share+225.2%/yr+45.9%/yr
Capital spending / share+145.1%/yr+23.4%/yr

The record, charted

FY2018–2025

Each measure over its full record; the current point and the worst year marked.

Share count
48Mpeak FY2019

Owner earnings vs. net income

Owner earningsNet income

The accountant's number, and the cash an owner can take; the gap is the tell.

(€34M)owner earningsvs.(€24M)net incomelow FY2019

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business reported a €24M loss but (€34M) of owner earnings: €10M less than the profit line, taken out by capital spending and the timing of cash.

FY2025FY2024FY2023FY2022FY2021
Reported net income(€24M)(€68M)(€40M)(€57M)(€47M)
Depreciation & amortizationnon-cash charge added back+€1M+€2M+€2M+€2M+€2M
Working capital & othertiming of cash in and out, other non-cash items−€11M+€47M+€26M+€18M+€16M
Cash from operations(€33M)(€20M)(€12M)(€37M)(€30M)
Capital expenditurecash put back in to keep running and to grow−€538K−€846K−€328K−€92K−€228K
Owner earnings(€34M)(€20M)(€13M)(€37M)(€30M)
Owner-earnings marginowner earnings ÷ revenue-104%284%-35%-779%-1137%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 20-F · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income (€11M) ÷ interest expense €15M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash, debt-free
    Cash €53M − debt €0
    What this means

    Cash and short-term investments exceed every dollar of debt by €53M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Not enough data
    Industry peers: median -66%
    What this means

    The filing data didn't include the inputs for this check.

  • Consumes cash through the cycle
    8-yr median margin, range -1663%–284%; latest (€34M) = operating cash (€33M) − maintenance capex €538K
    Industry peers: median -512%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -104% of revenue this year, a -779% median across 8 years.

  • Loss, and burning cash
    Net income (€24M) · cash from operations (€33M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 0.36×
    Harvesting
    Capex €538K ÷ depreciation €1M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Graham’s defensive tests · 0 of 3 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size
    Revenue ≥ $2B (a dollar floor) · €33M
    What this means

    Big enough to weather a storm. Graham's floor is a dollar figure — about $2B of revenue as a conservative modern stand-in. This company reports in its home currency and we carry no exchange rate, so we show the figure and leave the size bar for you to apply rather than convert it with a number we don't have.

  • Strong liquidity Miss
    Current ratio ≥ 2× · 1.09×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Earnings stability Miss
    A profit every year (8-yr record) · 8 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record Miss
    Uninterrupted dividends · none paid
    What this means

    An unbroken dividend was Graham's mark of durability. He wanted twenty years; the filings show about ten, and a single suspension breaks the streak. Non-payers, many fine modern compounders, fall outside his defensive net by design.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are €-0.00/share (latest year €-0.00), the averaged base the calculator's gate runs on, and book value is €-0.00/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2018–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 0 of 8
    What this means

    Lost money in 8 year(s), look at what happened there before trusting the average.

  • Operating margin −1385% → 281% (3-yr avg ends)
    What this means

    Through the cycle the operating margin widened — about −1385% early to 281% lately, median −978% — pricing power intact or improving.

  • Worst year 2021 · −1986.4% op. margin
    What this means

    Operations went underwater in 2021, understand why before trusting the good years.

Does AI threaten the moat?

Low contestability

The moat is physical, regulated or balance-sheet-funded, the kind AI cuts costs within but does not contest.

In its own filing Raised, but not as a competitor

The filing raises AI among its risks, but in other terms (security, regulation, energy or the like), not as a competitor to its product.

AI is unlikely to contest a moat that is physical, regulated or balance-sheet-funded; here it reads more as a cost tool than a threat.

Read from the filing's own risk factors, paired with the industry's structure under its SIC code; the durability is read above, the price below.

All figures as filed; the source filing is linked above.

Current Position

as of fiscal year-end, Dec 31, 2025

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets€63M
  • Cash & short-term investments€53M
  • Receivables€2M
  • Other current assets€8M
Current liabilities€58M
  • Accounts payable€9M
  • Other current liabilities€48M
Current ratio1.09×all current assets ÷ what's due · Graham looked for 2×
Quick ratioinventory untagged this quarter, so withheld rather than shown equal to the current ratio
Cash ratio0.92×strictest: cash alone against what's due
Working capital€5Mthe cushion left after near-term bills
Cash runway1.6 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Deeper floors
Tangible book value(€84M)equity stripped of goodwill & intangibles
Net current asset value(€89M)Graham's net-net: current assets less all liabilities
Deferred revenue€36Mcustomer cash collected before delivery; operating float

From the company's latest filing.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each figure is a through-cycle median, so a peak or trough year can’t distort it; the group median at the foot is the line to read each against.

CompanyRevenueGross marginOp. marginROICOwner earn. margin
SEPNSepterna Inc.$46M-148.6%-21%-6407%
AQSTAquestive Therapeutics Inc.$45M60%-72.6%-62%
PVLAPalvella Therapeutics Inc.$43M-124.9%-77%
WVEWave Life Sciences Ltd.$43M-935.3%-512%
RCUSArcus Biosciences Inc.$33M-656.8%-55%-503%
NBTXNanobiotix S.A.€33M-921.0%-769%
VSTMVerastem Inc.$31M99%-758.1%-78%-794%
ALMSAlumis Inc.$24M-1886.9%-169%-1539%
Group median-707.4%-641%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Enter the US price, in dollars: the NYSE/Nasdaq quote you hold. Per the filing's own cover, “American depositary shares, each representing one ordinary”; Nanobiotix S.A. reports in EUR, so every figure in this tool is stated per ADS and translated at EUR 1 = $1.145 (2026-07-17, reference rate) so your dollar quote reconciles exactly. The record tables elsewhere on this page remain as filed, in EUR.

Nanobiotix S.A. is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered117%/yr’20→’25

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−104%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Nanobiotix S.A. (NBTX), the owner's record," https://ownerscorecard.com/c/NBTX, data as of 2026-07-09.

Manual order: ← NAT its page in the Manual NCEW →

Industry order: ← NATR the Pharmaceuticals chapter NKTR →